# Codelist: Abuse-Deterrant Formulations - Opioids

_____

[Detailed study overview](https://www.opioiddata.org/studies/counfounding-opioid-safety-studies/) at the full project site [OpioidData.org](https://www.opioiddata.org)
<br>

_____

##### **Full list of NDCs for abuse-deterrent formulations of opioids for analytic purposes can be found [here](ADF_NDCs.csv)**

_____

|Drug Name|NDA#|Active Ingredients|Categories of Evidence|Intended Route of Deterrence|FDA Reference|Status|ER/IR|NDCs|FDA Documentation|
|---|---|---|--------|----------|------|---|---|---|---|
|OxyContin|22-272|Oxycodone Hydrochloride|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: OxyContin](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022272)|Active|ER|[OxyContin NDCs](OxyContin/oxycontin_NDCs.csv)|[OxyContin Documentation](OxyContin)|
|Hysingla ER|206627|Hydrocodone Bitartrate|**Intranasal & oral:** Category 1, Category 3<br>**Injection:** Category 1|Intravenous, intranasal, oral|[Drugs@FDA: Hysingla ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206627)|Active|ER|[Hysingla NDCs](Hysingla_ER/hysingla_NDCs.csv)|[Hysingla Documentation](Hysingla_ER)|
|MorphaBond ER|206544|Morphine Sulfate|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: MorphaBond ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206544)|Discontinued|ER|[MorphaBond NDCs](MorphaBond_ER/morphabond_NDCs.csv)|[MorphaBond Documentation](MorphaBond_ER)|
|Xtampza ER|208090|Oxycodone|**Intranasal & oral:** Category 1, Category 2, Category 3<br>**Injection: Category 1**|	Intravenous, intranasal, oral|[Drugs@FDA: Xtampza ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208090)|Active|ER|[Xtampza NDCs](Xtampza_ER/xtampza_NDCs.csv)|[Xtampza Documentation](Xtampza)|
|RoxyBond|209777|Oxycodone Hydrochloride|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: RoxyBond](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209777)|Discontinued|IR| |[RoxyBond Documentation](RoxyBond)|
|Embeda|022321|Morphine Sulfate; Naltrexone Hydrochloride|**Oral & Intranasal:** Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Embeda](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)|Discontinued|ER|[Embeda NDCs](Embeda/embeda_NDCs.csv)|[Embeda Documentation](Embeda)|
|Arymo ER|208603|Morphine Sulfate|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: Arymo ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)|Discontinued|ER|[Arymo NDCs](Arymo_ER/arymo_NDCs.csv)|[Arymo Documentation](Arymo)|
|Targiniq|205777|Naloxone Hydrochloride; Oxycodone Hydrochloride|Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: Targiniq](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)|Discontinued|ER| |[Targiniq Documentation](Targiniq)|
|Troxyca ER|207621|Naltrexone Hydrochloride; Oxycodone Hydrochloride|Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Troxyca ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)|Discontinued|ER| |[Troxyca Documentation](Troxyca)|
|Oxaydo/Oxecta|202080|Oxycodone Hydrochloride|Category 3|Intranasal|[Drugs@FDA: Oxaydo](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)|Active|IR|[Oxaydo/Oxecta NDCs](Oxaydo/oxaydo_NDCs.csv)|[Oxaydo Documentation](Oxaydo)|
